The PSA-TRICOM platform employs a strategic approach wherein it enables the expression of prostate-specific antigen, a marker for prostate cancer while incorporating three T cell receptor-stimulating co-regulators (TRICOM). This evidence concerns the gene KLK3 and Familial prostate cancer.